Ketamin (Ketamine Hydrochloride)

Ketamine blocks the NMDA subtype of glutamate receptors, decreasing excitatory neurotransmission and producing dissociative anesthesia. It also interacts with opioid receptors and monoamine pathways, which contributes to its analgesic and, in certain cases, antidepressant properties.

The dose of Ketamin is individualized by the prescribing clinician based on the indication, patient weight, age, and clinical setting. Dosage regimens are determined by qualified health‑care professionals and are not disclosed in public product literature.

Safety data for ketamine in pregnancy and lactation are limited. The product is classified as having an unknown pregnancy category, and clinicians should weigh potential benefits against risks before use in pregnant or nursing patients.

To request Ketamin, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where needed) and import documentation.

Ketamin differs from traditional inhalational or opioid anesthetics by providing dissociative anesthesia while preserving airway reflexes and cardiovascular stability. Unlike pure sedatives, it offers potent analgesia, but it may cause psychomimetic effects that are less common with agents such as propofol or sevoflurane.

Ketamin should be stored below 25 °C in its original packaging, protected from light and moisture. Maintaining a stable room‑temperature environment helps preserve potency and sterility of the injectable solution.

Ketamin is supplied as a sterile injectable solution and is administered either intramuscularly or intravenously by a qualified health‑care professional. The route, rate of infusion, and total dose are determined by the treating clinician according to the specific clinical indication.

Serious risks include respiratory depression, severe hypertension or cardiac arrhythmias, emergence delirium or psychotic reactions, and rare allergic responses such as anaphylaxis. Continuous monitoring of airway, cardiovascular status, and mental state is essential during and after administration.

Ketamin is contraindicated in patients with known hypersensitivity to ketamine or its excipients, uncontrolled elevated intracranial pressure, severe cardiovascular disease where rapid blood pressure changes are hazardous, and in individuals with a history of severe psychiatric disorders that may be exacerbated by dissociative effects.